The development of resistance to tamoxifen in patients with breast cancer: our experience

Sinisa Maksimovic, Biljana Marjanovic, Branislava Jakovljevic, Zdenka Gojkovic, Dejan Opric, Dusan Mileusnic


Background: The study used data from medical and counselling of patients who were diagnosed with hormone-dependent breast cancer. Aim: The objective of the paper is to identify within a group of patients diagnosed with hormone sensitive breast cancer and those who have received adjuvant tamoxifen, and then to isolate the patients with whom the therapeutic effect of tamoxifen stopped (resistance to tamoxifen).

Methods: The study analyzed 153 patients in the period from 2005 to 2011, at the Public Health Institution Hospital, Sveti Vračevi" in Bijeljina. Resistance to tamoxifen was developed by 60 patients (39.2%) and 93 patients (60.8%) did not develop resistance to it.

Results: More common emergence of resistance is in the premenopausal group of patients (p<0.001). Statistically significant difference in frequency of resistance to tamoxifen was observed in the group of patients with ER-/PrR+ status of steroid receptors (p<0.001). In relation to HER-2 status of diagnosed cancer, a statistically significant difference in frequency of resistance emergence during tamoxifen therapy in patients with HER2-positive status (p<0.001) was observed. We found that there is a statistically significant difference between patients with metastatic in lymph nodes compared to patients who had no metastases in lymph nodes (X2=39.494; p<0.001).

Conclusions: The analysis of menopausal status of patients, status of ER/PgR receptors status, HER-2 status of diagnosed cancer and status of lymph nodes trying to sort out the parameters on the basis of which a group of patients who can be expected to develop resistance to tamoxifen could be differentiated.


Breast cancer, Tamoxifen, Resistance

Full Text:



Sengupta S, Biarnes MC, Jordan VC. Cyclin dependent kinase-9 mediated transcriptional de regulation of cMYC as a critical determinant of endocrine-therapy resistance in breast cancers. Breast Cancer Res and Treat. 2014;143:113-24.

Madeira M, Mattar A, Logullo AF. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer. 2013;13:425-30.

Rieber M, Strasberg-Rieber M. p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptibility to 3-bromopyruvate in ER𝛼 + breast cancer MCF-7 cells. Bioch Pharm. 2014;88:169-77.

Martinez-Galan J, Torres-Torres B, Isabel N´u˜nez M. ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer. 2014;14:59-63.

Gnant M, Greil R, Hubalek M, Steger G. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an Austrian expert panel discussion. Breast Care. 2014;8:293-9.

Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan-Melkumian V, et al. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res Treat. 2014;143:325-32.

Hefti MM, Hu R, Knoblauch NW. Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. Breast Cancer Res. 2013;11:68-73.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, et al. Endopredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013;24:640-7.

Ellis MJ, Suman VJ, Hoog J. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011;9:2342-9.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVriesa C, Pluschniga U, Dubsky P, et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer. 2012;48:1932-8.

Doughty JC. When to start an aromatase inhibitor: now or later? J Surg Oncol. 2011;103:730-8.

Caldon CE, Sergio CM, Kang J. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Therap. 2012;11:1488-99.

Diaz Flaque MC, Galigniana NM, B´eguelin W, Vicario R, Proietti CJ, Russo R, et al. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res. 2013;15:118-21.

Wang D, Huang P, Zhu B. Induction of estrogen receptor 𝛼-36 expression by bone morphogenetic protein 2 in breast cancer cell lines, Mol Med Rep. 2012;6:591–596.

Saleh RR, Bouganim N, Hilton J. Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again? Current Oncol. 2014;21:122-8.

Baselga J, Campone M, Piccart M. verolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520-9.